Education
About Us
Working with TipRanks
Follow Us
Adaptive Biotechnologies Corp (ADPT)
NASDAQ:ADPT
Earnings Data
Report Date
Apr 30, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.29Last Year’s EPS
-0.33Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 11, 2025
|% Change Since: -4.23%
|Next Earnings Date:Apr 30, 2025
Earnings Call Sentiment|Positive
The earnings call presented a positive view of Adaptive Biotechnologies' performance for 2024, highlighting significant growth in MRD revenue, improvements in operational efficiency, and a strong cash position. These positive developments were slightly offset by challenges in the immune medicine segment and a conservative outlook for MRD Pharma Services.Company Guidance
During Adaptive Biotechnologies' Q4 and full-year 2024 earnings call, the company reported significant progress and financial metrics. MRD (Minimal Residual Disease) revenue increased by 42% compared to 2023, driven by a new gap fill rate for clonoSEQ tests set at $2,007, and the ODAC's favorable vote for MRD as a primary endpoint in multiple myeloma therapies. ClonoSEQ's clinical revenue grew 40% year-over-year, with a record 20,945 tests delivered in Q4, marking a 34% increase. Blood-based MRD testing rose by 55%, contributing to 41% of U.S. tests, while ordering healthcare providers grew by 30%. The company reported a robust cash position of $256 million at year-end and aims for an ASP of $1,300 per test in 2025, with MRD revenue projected to grow 24-30%. The guidance reflects a strategic focus on expanding blood-based testing, further integration with EPIC accounts, and leveraging commercial partnerships like the one with NeoGenomics.MRD Revenue Growth
Revenue increased 42% versus 2023, driven by both clinical testing and pharma. This included a new gap fill rate for the clonoSEQ test and an ODAC vote supporting the use of MRD as a primary endpoint for multi myeloma therapies.
clonoSEQ Clinical Revenue and Test Volume Growth
Full year clonoSEQ clinical revenue grew 40% versus prior year, with a record high of 20,945 tests delivered in the fourth quarter, representing a 34% increase versus prior year.
Cash Position and Reduction in Cash Burn
Concluded the year with a cash position of $256 million and achieved a 40% reduction in cash burn from 2023.
Immune Medicine Progress
Significant progress in autoimmune programs with a nominated lead clinical indication and a focus on preclinical development of an antibody therapeutic candidate.
Operational Efficiency and Cost Management
Improved sequencing gross margin to 59% for the fourth quarter, total operating spend decreased by 11% year-over-year.
---
ADPT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ADPT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 11, 2025 | $7.80 | $7.55 | -3.21% |
| Nov 07, 2024 | $5.63 | $5.82 | +3.37% |
| Aug 01, 2024 | $4.45 | $4.30 | -3.37% |
| May 07, 2024 | $3.11 | $3.18 | +2.25% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Adaptive Biotechnologies Corp (ADPT) report earnings?
Adaptive Biotechnologies Corp (ADPT) is schdueled to report earning on Apr 30, 2025, TBA Not Confirmed.
What is Adaptive Biotechnologies Corp (ADPT) earnings time?
Adaptive Biotechnologies Corp (ADPT) earnings time is at Apr 30, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ADPT EPS forecast?
ADPT EPS forecast for the fiscal quarter 2025 (Q1) is -0.29.
---